Business · 16/02/2021Updated: 10/17/2026 · 1 min read
FDA Awards Priority Review Voucher to Alnylam Pharmaceuticals for Rare Pediatric Disease Product OXLUMO
Summary
The FDA has awarded a priority review voucher to Alnylam Pharmaceuticals for its rare pediatric disease product OXLUMO, following a review of the product's eligibility under the FD&C Act and FDASIA.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →